MedPacto Appoints Lee Ji-hoon as New CSO
MedPacto announced on the 21st that it has newly appointed Lee Ji-hoon as Chief Strategy Officer (CSO).
Director Lee is a business development (BD) expert with extensive understanding and experience in the pharmaceutical and bio industries. He has been responsible for discovering new businesses while working at LG Life Sciences (now LG Chem Life Sciences Division) and HK Innoen. Most recently at HK Innoen, he served as the head of the global business unit, overseeing global operations and handling new business and investment tasks. He has promoted various forms of business development in the pharmaceutical and bio fields, including joint research, strategic investment, partnerships, and technology transfers. He is also said to have experience in establishing R&D portfolio strategies and managing mid- to long-term R&D strategies.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Why This Bonus Grade?" Civil Servant Who Assaulted HR Employee... Court Rules Demotion Is Justified
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A MedPacto official stated, “Director Lee has extensive experience in business development in the pharmaceutical and bio sectors,” and added, “We expect him to play a key role in BD, including joint development and technology transfers of MedPacto’s pipeline.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
